Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Praxis Precision Medicines, Inc. - Common Stock (NQ: PRAX )

65.84 +1.82 (+2.84%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Praxis Precision Medicines, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Praxis Precision Medicines Says PRAX-628 Can Potentially Be The Best-In-Class Treatment For Focal Epilepsy
Praxis Precision Medicines Inc (NASDAQ: PRAX) announced topline results from the PRAX-628 Phase 1 healthy volunteer study evaluating single ascending doses (SAD) and  
Via Benzinga
Recap: Praxis Precision Medicine Q1 Earnings
Via Benzinga
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2023 Financial Results
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Announces Positive Topline Results from PRAX-628 Phase 1 Study Enabling Best-in-Class Profile
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Outlines Upcoming Plans For Pediatric Epilepsy Programs
Via Benzinga
Praxis Precision Medicines to Present at the American Academy of Neurology 2023 Annual Meeting
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Announces Upcoming Ulixacaltamide Presentations & Events
Ulixacaltamide essential tremor end-of-phase 2 meeting with FDA scheduled for June 2023 
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Present at 22nd Annual Needham Virtual Healthcare Conference
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank
The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 6, 2023
Via Benzinga
Praxis Precision Medicines to Present at Upcoming Investor Conferences
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Dow Jumps Over 300 Points; S&P 500 Rises 1.5%
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 300 points on Friday. The Dow traded up 1.03% to 33,343.73 while the NASDAQ rose 1.92% to 11,682.86. The S&P... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Nasdaq Up 150 Points; Crude Oil Rises 1%
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 150 points on Friday. The Dow traded up 0.59% to 33,197.08 while the NASDAQ rose 1.32% to 11,614.60. The S&P... 
Via Benzinga
Why Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers ObsEva SA (NASDAQ: OBSV) surged 86.6% to $0.1978 after dropping over 12% on Thursday. ObsEva recently announced strategic reorganization to consolidate operations in Switzerland. 
Via Benzinga
Dow Surges Over 100 Points; US Services PMI Rises In February
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Friday. Following the market opening Friday, the Dow traded up 0.42% to 33,140.85 while the NASDAQ rose 1.02%... 
Via Benzinga
Despite Trial Failure Praxis Still Seeks Advancing Essential Tremor Program Into Phase 3 Study
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Praxis Precision Medicines Announces Topline Results from the Essential1 Study of Ulixacaltamide for the Treatment of Essential Tremor and Continued Advancement of Program to Phase 3
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off Tuesday with a look at the biggest pre-market stock movers that traders will want to keep an eye on today! 
Via InvestorPlace
US Stocks Edge Lower; Bank of America Profit Tops Views
U.S. stocks traded lower this morning, with the Dow Jones dropping around 50 points on Friday. 
Via Benzinga
Praxis Precision Medicines and UCB Announce Epilepsy Research Collaboration
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Present at the American Epilepsy Society 2022 Annual Meeting
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Advance PRAX-562 Phase 2 Study in Pediatric Patients with Developmental and Epileptic Encephalopathies
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2022 Financial Results
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Present at Upcoming Investor Conferences
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Why Laser Photonics Shares Surged By Around 19%; Here Are 70 Biggest Movers From Friday
Gainers Agrify Corporation (NASDAQ: AGFY) climbed 53.8% to close at $1.45. FedNat Holding Company (NASDAQ: FNHC) gained 48% to settle at $0.52. 
Via Benzinga
Ambit Inc. to Present Novel Projection Methodology for Rare Developmental and Epileptic Encephalopathies (DEEs) at the 2022 Child Neurology Society Annual Meeting
Ambit to showcase its prevalence projection approach, co-developed with Praxis, for rare developmental and epileptic encephalopathies (DEEs) as a Platform Presentation at this year's annual Child... 
Via Newswire.com
Needham Previews Neurocrine's Upcoming Mid-Stage Data from Essential Tremor Study
Needham previews the upcoming Phase 2 data readout for Neurocrine Biosciences Inc's (NASDAQ: NBIX) NBI-827104, a t-type calcium channel blocker in essential tremor (ET), by mid-2022. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.